Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 10:17 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 386 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Zilretta Clear all
Not listed Phase 1Phase 2 Interventional

Mesenchymal Stem Cell Therapy for Knee Osteoarthritis

NCT05288725
View directory record Official record
Conditions
Osteoarthritis, Knee
Interventions
Bone Marrow Derived MSCs, Corticosteroid, Bone Marrow Aspirate
Biological · Drug · Device
Lead sponsor
Next Generation Regenerative Medicine LLC
Network
Eligibility
18 Years to 80 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
3
States / cities
Chesterfield, Missouri • Steubenville, Ohio • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 20, 2022 · Synced Sep 2, 2026, 10:17 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Kybella With Triamcinolone

NCT03361176
View directory record Official record
Conditions
Adiposity
Interventions
Injectable sodium deoxycholate, Injectable sodium deoxycholate with Triamcinolone acetate
Drug · Combination Product
Lead sponsor
Goldman, Butterwick, Fitzpatrick and Groff
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
2
States / cities
San Diego, California • Hunt Valley, Maryland
Source: ClinicalTrials.gov public record
Updated May 8, 2019 · Synced Sep 2, 2026, 10:17 PM EDT
Completed Not applicable Interventional Results available

Study of Safety and Efficacy for the Eustachian Tube Balloon Catheter

NCT02087150
View directory record Official record
Conditions
Eustachian Tube Dysfunction
Interventions
Acclarent Eustachian Tube Balloon Catheter (ETBC)
Device
Lead sponsor
Integra LifeSciences Corporation
Industry
Eligibility
22 Years and older
Enrollment
323 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
21
States / cities
East Palo Alto, California • Washington D.C., District of Columbia • Boca Raton, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2024 · Synced Sep 2, 2026, 10:17 PM EDT
Completed Phase 2 Interventional Results available

Human Anti-Tac (Daclizumab) to Treat Juvenile Idiopathic Arthritis (JIA)-Associated Uveitis

NCT00130637
View directory record Official record
Conditions
Anterior Uveitis, Arthritis, Juvenile Idiopathic, Iritis, Immunosuppression
Interventions
Daclizumab
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
6 Years to 18 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 29, 2017 · Synced Sep 2, 2026, 10:17 PM EDT
Completed Not applicable Interventional Results available

Steroid Injection vs. BioDRestore for Patients With Knee OA

NCT02767492
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
BioD Restore, Kenalog
Device · Drug
Lead sponsor
The Hawkins Foundation
Other
Eligibility
18 Years to 80 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Greenville, South Carolina
Source: ClinicalTrials.gov public record
Updated Nov 22, 2021 · Synced Sep 2, 2026, 10:17 PM EDT
Completed Phase 1Phase 2 Interventional

To Study the Effects of CD25 and Low Dose Cyclosporin in the Treatment of Active Psoriasis Vulgaris

NCT00050648
View directory record Official record
Conditions
Psoriasis
Interventions
Daclizumab, Cyclosporine, cyclosporine and Daclizumab
Drug
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2008
U.S. locations
3
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 12, 2009 · Synced Sep 2, 2026, 10:17 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Study of a New Dressing for Use With Topical Medications

NCT00234728
View directory record Official record
Conditions
Psoriasis
Interventions
Occlusive dressing
Device
Lead sponsor
Teikoku Pharma USA, Inc.
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 1, 2008 · Synced Sep 2, 2026, 10:17 PM EDT
Completed Phase 1Phase 2 Interventional Results available

20089 TA+Lucentis Combo Intravitreal Injections for Treatment of Neovascular Age-related Macular Degeneration (AMD)

NCT01175395
View directory record Official record
Conditions
Age-Related Macular Degeneration, Choroidal Neovascularization
Interventions
IBI-20089/Lucentis
Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
55 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 19, 2014 · Synced Sep 2, 2026, 10:17 PM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

The Effect of Local Analgesia on Postoperative Gluteal Pain in Patients Undergoing Sacrospinous Ligament Fixation

NCT03995641
View directory record Official record
Conditions
Postoperative Pain, Pelvic Organ Prolapse, Trigger Point Injection, Sacrospinous Ligament Fixation
Interventions
marcaine and kenalog
Drug
Lead sponsor
Kettering Health Network
Other
Eligibility
21 Years and older · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
Dayton, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 4, 2025 · Synced Sep 2, 2026, 10:17 PM EDT
Withdrawn Not applicable Interventional

Effect of Celiac Plexus Block on Gastric Emptying and Symptoms Caused by Gastroparesis

NCT02420925
View directory record Official record
Conditions
Gastroparesis
Interventions
Celiac Plexus Block
Procedure
Lead sponsor
Linda Nguyen
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Aug 27, 2020 · Synced Sep 2, 2026, 10:17 PM EDT
Completed Phase 3 Interventional Results available

A Study of Hyaluronan for the Treatment of Osteoarthritis in the Thumb

NCT00398866
View directory record Official record
Conditions
Osteoarthritis
Interventions
Synvisc (Hylan G-F20; hyaluronan injection), Bupivicaine (local anesthesia injection), Kenalog (triamcinolone; corticosteroid injection)
Drug
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
45 Years to 95 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 6, 2017 · Synced Sep 2, 2026, 10:17 PM EDT
Terminated Not applicable Interventional

Single Blinded First CMC Osteoarthritis Treatment

NCT03196310
View directory record Official record
Conditions
Osteoarthritis Thumb
Interventions
Platelet Concentrate, Corticosteroid injection, Normal Saline
Drug · Other
Lead sponsor
Kettering Health Network
Other
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Centerville, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Sep 2, 2026, 10:17 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Optimal Anesthetic for Corticosteroid Injections for Knee Osteoarthritis

NCT05906433
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
Kenalog with bupivacaine Injection
Drug
Lead sponsor
Foundation for Orthopaedic Research and Education
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Dec 8, 2024 · Synced Sep 2, 2026, 10:17 PM EDT
Completed Phase 2 Interventional

A Study to Evaluate the Safety of Lebrikizumab Compared to Topical Corticosteroids in Adult Patients With Atopic Dermatitis

NCT02465606
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Lebrikizumab, Topical Corticosteroid Creams (Triamcinolone acetonide 0.1% and Hydrocortisone 2.5%)
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 75 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
12
States / cities
Encino, California • Granada Hills, California • Mission Viejo, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2020 · Synced Sep 2, 2026, 10:17 PM EDT
Terminated Phase 2 Interventional Results available

Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Liver Transplant Recipients With Additional 12-month Follow-up and Long-term Extension

NCT03781414
View directory record Official record
Conditions
Liver Transplant Rejection
Interventions
CFZ533, Tacrolimus - MMF - corticosteroids
Biological · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
9
States / cities
Los Angeles, California • Aurora, Colorado • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated May 15, 2025 · Synced Sep 2, 2026, 10:17 PM EDT
Recruiting Phase 2 Interventional

TriCalm Hydrogel® in the Treatment of Immunotherapy-Related Pruritus

NCT06748404
View directory record Official record
Conditions
Immunotherapy-related Pruritus
Interventions
TriCalm Hydrogel®, Triamcinolone acetonide 0.1% cream
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Sep 2, 2026, 10:17 PM EDT
Not yet recruiting Phase 2 Interventional Accepts healthy volunteers

Long Duration High Frequency Ultrasound for the Treatment of Osteoarthritis

NCT07515872
View directory record Official record
Conditions
Arthritis, Osteo Arthritis of the Knee
Interventions
Sustained Acoustic Device with 2.5% Diclofenac Patch, Sustained Acoustic Device with 0% Diclofenac Patch, Intra articular injection
Device · Drug
Lead sponsor
ZetrOZ, Inc.
Industry
Eligibility
65 Years to 85 Years
Enrollment
240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
2
States / cities
Stamford, Connecticut • Dryden, New York
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Sep 2, 2026, 10:17 PM EDT
Completed Phase 3 Interventional Results available

Study to Assess the Efficacy and Long-term Safety of Dupilumab (REGN668/SAR231893) in Adult Participants With Moderate-to-Severe Atopic Dermatitis

NCT02260986
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Dupilumab, Placebo (for Dupilumab), Topical Corticosteroid (TCS)
Drug · Other
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
740 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
50
States / cities
Phoenix, Arizona • Hot Springs, Arkansas • Little Rock, Arkansas + 47 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2017 · Synced Sep 2, 2026, 10:17 PM EDT
Completed Phase 4 Interventional Results available

Nasacort AQ Hypothalamic-Pituitary-Adrenal (HPA) Axis Study in Children With Allergic Rhinitis

NCT01154153
View directory record Official record
Conditions
Rhinitis, Allergic, Perennial and/or Seasonal
Interventions
Placebo nasal spray, Triamcinolone acetonide aqueous (TAA-AQ) nasal spray (NASACORT AQ), Claritin® Syrup
Drug
Lead sponsor
Sanofi
Industry
Eligibility
2 Years to 12 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
8
States / cities
Cypress, California • Stockbridge, Georgia • North Dartmouth, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2012 · Synced Sep 2, 2026, 10:17 PM EDT
Not listed Phase 3 Interventional

Randomized Placebo-controlled Analysis of Superior Laryngeal Nerve Block for Neurogenic Cough

NCT04468542
View directory record Official record
Conditions
Cough, Nerve Block
Interventions
Superior laryngeal nerve block - Intervention (Bupivacaine and triamcinolone acetonide suspension), Superior laryngeal nerve block - Placebo (saline)
Drug
Lead sponsor
University of South Florida
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Nov 7, 2022 · Synced Sep 2, 2026, 10:17 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

PeriOcular and INTravitreal Corticosteroids for Uveitic Macular Edema Trial

NCT02374060
View directory record Official record
Conditions
Macular Edema, Uveitis
Interventions
Periocular triamcinolone 40 mg, Intravitreal triamcinolone 4 mg, Dexamethasone intravitreal implant
Drug
Lead sponsor
JHSPH Center for Clinical Trials
Other
Eligibility
18 Years and older
Enrollment
192 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
23
States / cities
Los Angeles, California • San Francisco, California • Miami, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2018 · Synced Sep 2, 2026, 10:17 PM EDT
Terminated Phase 2 Interventional Results available

Proof of Concept Study Comparing FX006 to Kenalog®-40 in Patients With Post-Traumatic Osteoarthritis of the Knee

NCT02468583
View directory record Official record
Conditions
Post-traumatic Osteoarthritis of the Knee
Interventions
FX006 32 mg, TCA IR 40 mg
Drug
Lead sponsor
Pacira Pharmaceuticals, Inc
Industry
Eligibility
20 Years to 50 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 23, 2024 · Synced Sep 2, 2026, 10:17 PM EDT
Completed Not applicable Interventional Results available

Fractional Ablative Laser Treatment for Skin Grafts

NCT04176705
View directory record Official record
Conditions
Burn Scar, Skin Graft Scar
Interventions
Lidocaine Cream, Triamcinolone Acetonide Cream, Fractional Ablative Laser
Drug · Device
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 28, 2024 · Synced Sep 2, 2026, 10:17 PM EDT
Completed Phase 2 Interventional

Eflornithine With or Without Triamcinolone in Preventing Nonmelanoma Skin Cancer in Patients With Actinic Keratosis

NCT00021294
View directory record Official record
Conditions
Non-melanomatous Skin Cancer, Precancerous/Nonmalignant Condition
Interventions
eflornithine, triamcinolone
Drug
Lead sponsor
University of Arizona
Other
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2002
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 10, 2018 · Synced Sep 2, 2026, 10:17 PM EDT